-
Innovation Ranking
NewInnovation Ranking – China National Nuclear Power Co Ltd
China National Nuclear Power Co Ltd (CNNPC), a subsidiary of China National Nuclear Corp is a nuclear energy plant construction company. The company's business activities comprise the development, investment, construction, operations, and management of nuclear power and clean energy projects. It also invests in power transmission and distribution projects; and carries out technical research in the operation of nuclear power plants. CNNPC caters to nuclear electricity generation, nuclear fuels, nuclear military, nuclear power, nuclear technology applications, and others. The company's...
-
Product Insights
Nuclear Receptor ROR Gamma – Drugs In Development, 2023
Global Markets Direct’s Nuclear Receptor ROR Gamma provides in depth analysis on Nuclear Receptor ROR Gamma targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR...
-
Product Insights
Nuclear Factor Erythroid 2 Related Factor 2 – Drugs In Development, 2023
Global Markets Direct’s Nuclear Factor Erythroid 2 Related Factor 2 provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Nuclear Receptor Subfamily 4 Group A Member 2 – Drugs In Development, 2023
Global Markets Direct’s Nuclear Receptor Subfamily 4 Group A Member 2 provides in depth analysis on Nuclear Receptor Subfamily 4 Group A Member 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview...
-
Product Insights
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta – Drugs In Development, 2023
Global Markets Direct’s Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta provides in depth analysis on Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...
-
Product Insights
Nuclear Receptor Subfamily 2 Group F Member 6 – Drugs In Development, 2023
Global Markets Direct’s Nuclear Receptor Subfamily 2 Group F Member 6 provides in depth analysis on Nuclear Receptor Subfamily 2 Group F Member 6 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview...
-
Product Insights
NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) - Drugs In Development, 2023’, provides an overview of the NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The...
-
Sector Analysis
Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Nuclear Imaging Systems Market Report Overview The nuclear imaging systems market size was valued at $1.07 billion in 2023. The nuclear imaging systems market will grow at a CAGR of more than 2% from 2023 to 2033. Nuclear Imaging is a non-invasive medical technique that uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases, including cancers, cardiac diseases, gastrointestinal, endocrine, and neurological diseases. Nuclear Imaging Systems Market Outlook 2023-2033 ($ Billion) Buy the Full Report...
-
Sector Analysis
United States (US) Nuclear Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
United States (US) Nuclear Power Market Report Overview The cumulative capacity for nuclear power in the US was 94.7 GW in 2022. The market is anticipated to decline at a negative CAGR of less than 1% from 2023 to 2035. The US nuclear power market research report highlights installed capacity and power generation trends from 2010 to 2035. The report discusses the key insights about the major active and upcoming nuclear power plants in the US. US Nuclear Power Market...
-
Sector Analysis
Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Nuclear Imaging Equipment Market Report Overview The nuclear imaging equipment market size was valued at $2.90 billion in 2023 and is expected to grow at a CAGR of more than 7% during 2023 and 2033. Nuclear imaging is a non-invasive medical technique that uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases. The diseases include cancers, cardiac diseases, gastrointestinal, endocrine, and neurological diseases. Nuclear Imaging Equipment Market Outlook 2023-2033 ($ Billion) Buy The Full Report...